BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29895190)

  • 1. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.
    Engelke CG; Parsels LA; Qian Y; Zhang Q; Karnak D; Robertson JR; Tanska DM; Wei D; Davis MA; Parsels JD; Zhao L; Greenson JK; Lawrence TS; Maybaum J; Morgan MA
    Clin Cancer Res; 2013 Aug; 19(16):4412-21. PubMed ID: 23804422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
    Parsels LA; Tanska DM; Parsels JD; Zabludoff SD; Cuneo KC; Lawrence TS; Maybaum J; Morgan MA
    Cell Cycle; 2016; 15(5):730-9. PubMed ID: 26890478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
    Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
    Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
    Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
    Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
    Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
    Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
    Warren NJH; Eastman A
    J Biol Chem; 2019 Feb; 294(6):1763-1778. PubMed ID: 30573684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
    Saini P; Li Y; Dobbelstein M
    Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
    Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
    Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
    Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
    Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
    Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T
    Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the
    Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775.
    Hauge S; Macurek L; Syljuåsen RG
    Cell Cycle; 2019 Apr; 18(8):834-847. PubMed ID: 30943845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.